This troubled biotech needed cash, so it turned to a predatory lender: its own CEO
This troubled biotech needed cash, so it turned to a predatory lender: its own CEO.
by Adam Feuerstein
Aug 19, 2019
2 minutes
I don’t write about Northwest Biotherapeutics much anymore because it’s not cool to punch down. However, there was a juicy nugget in the cancer biotech’s recently filed 10-Q that had to be shared. It’s another example of a biotech executive getting rich at the expense of shareholders and patients.
You’re reading a preview, subscribe to read more.
Start your free 30 days